Update on anti-CTLA-4 antibodies in clinical trials.

Published

Journal Article (Review)

Breaking immune tolerance against tumor self-antigens is presently an area of intense research in the design of cancer therapies. One possible method to enhance immune system activation against tumor antigens is by blocking the inhibitory co-stimulatory signals mediated by cytotoxic T lymphocyte antigen 4, (CTLA-4) expressed on activated T cells. The fully human monoclonal antibodies that are directed against human CTLA-4, ipilimumab (Medarex/Bristol-Myers Squibb) and CP-675,206 (Pfizer/Abgenix, now Amgen), have demonstrated activity against metastatic melanoma, hormone refractory prostate cancer and other malignancies. They have also uncovered unusual immune-related adverse events manifesting as self-limiting inflammatory reactions of the bowel, skin and pituitary. This article reviews preclinical development and data generated from Phase I, II and III studies with regard to the end points reported and immune-related adverse events.

Full Text

Duke Authors

Cited Authors

  • Langer, LF; Clay, TM; Morse, MA

Published Date

  • August 2007

Published In

Volume / Issue

  • 7 / 8

Start / End Page

  • 1245 - 1256

PubMed ID

  • 17696822

Pubmed Central ID

  • 17696822

Electronic International Standard Serial Number (EISSN)

  • 1744-7682

International Standard Serial Number (ISSN)

  • 1471-2598

Digital Object Identifier (DOI)

  • 10.1517/14712598.7.8.1245

Language

  • eng